Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial

Journal of the National Cancer Institute

Volumn 94, Issue 3, 2002, Pages 173-181

  Langer, Corey J ^a   Manola, Judith ^b   Bernardo, Patricia ^b   Kugler, John W ^c   Bonomi, Philip ^d   Cella, David ^e   Johnson, David H ^f  

^a FOX CHASE CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Illinois Oncology Research Association   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; PLATINUM;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG USE; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; INCIDENCE; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; OUTCOMES RESEARCH; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOPATHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; WEIGHT REDUCTION; WELLBEING;

EID: 0037028750     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.3.173     Document Type: Article

References (35)

1. Lung cancer in the elderly patient
2. Underrepresentation of patients 65 years of age or older in cancer-treatment trials
3. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
4. Relative survival in elderly cancer patients in Europe
5. Cancer patient survival in the elderly
6. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer
7. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience
8. Long-term survivors in metastatic non-small-cell lung cancer
9. Prognostic factors in advanced non-small cell lung cancer (NSCLC): Analysis of Eastern Cooperative Oncology Group (ECOG) trials from 1981-1992
10. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Oncology Group trial
11. Prognostic factors for survival in patients with inoperable lung cancer
12. A new international staging system for lung cancer
13. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument
14. Toxicity and response criteria of the Eastern Cooperative Oncology Group
15. A multiple testing procedure for clinical trials
16. Discrete sequential boundaries for clinical trials
17. Use of ranks in one criterion of variance analysis
18. Nonparametric estimation from incomplete estimation
19. Evaluation of survival data and two new rank order statistics arise in its consideration
20. Mathematical statistics: Basic ideas and selected topics
21. Exact significance testing for ordered categorical data
22. Methods for the analysis of informatively censored longitudinal data
23. Random-effects models for longitudinal data
24. Lack of age-dependent cisplatin nephrotoxicity
25. Physiologic aspects of aging. Implications for the treatment of cancer
26. Cancer and aging. An evolving panorama
27. Cancer chemotherapy in the older person: What the oncologist needs to know
28. Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
29. Gemcitabine in the treatment of the elderly patient with advanced non-small cell lung carcinoma
30. Effect of age on gemcitabine toxicity profile in efficacy in advanced non-small cell lung cancer
31. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer
32. The MILES (Multicenter Italian Lung Cancer in the Elderly Study) Phase III Trial: GemcitabineG and vinorelbine vs vinorelbine and vs gemcitabine in elderly advanced non-small cell lung cancer
33. Advancing age does not exacerbate toxicity or compromise outcome in NSCLC patients receiving paclitaxel-carboplatin
34. Cancer in older persons: Magnitude of the problem-how do we apply what we know?